Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2019-07-03
2020-01-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study arm 1
Allin capsules (x2) and Sulforaphane capsules (x2) once daily for 4 weeks
Allin
Dietary supplement
Sulforaphane
Dietary supplement
Study arm 2
Allin capsules (x2) and placebo capsules (x2) once daily for 4 weeks
Allin
Dietary supplement
Placebo
Dietary supplement
Study arm 3
Sulforaphane capsules (x2) and placebo capsules (x2) once daily for 4 weeks
Sulforaphane
Dietary supplement
Placebo
Dietary supplement
Study arm 4
Placebo capsules (x4) once daily for 4 weeks
Placebo
Dietary supplement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allin
Dietary supplement
Sulforaphane
Dietary supplement
Placebo
Dietary supplement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 19.5 and 35 kg/m2
* Smokers and non-smokers
Exclusion Criteria
* Those on warfarin treatment
* Those diagnosed with diabetes
* Those diagnosed with or suspected to be high-risk for human immunodeficiency virus (HIV) and/or viral hepatitis
* Those allergic to any of the ingredients included in the supplements (including those with lactose intolerance)
* Those taking additional dietary supplements or herbal remedies that could affect the study outcome.
* Those that are unable to understand English or give informed consent
* Parallel participation in another research project that involves dietary intervention
* Any person related to or living with any member of the study team.
18 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)
OTHER
Quadram Institute Bioscience
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard Mithen, pHD
Role: PRINCIPAL_INVESTIGATOR
Quadram Institute Bioscience
Robert Mills, Dr
Role: PRINCIPAL_INVESTIGATOR
Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Quadram Institute Bioscience
Norwich, Norfolk, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QIB01/2019
Identifier Type: -
Identifier Source: org_study_id